A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions
Authors
Keywords
-
Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 64, Issue 5, Pages 2312-2338
Publisher
American Chemical Society (ACS)
Online
2021-02-23
DOI
10.1021/acs.jmedchem.0c01516
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ubrogepant: First Approval
- (2020) Lesley J. Scott DRUGS
- Golodirsen: First Approval
- (2020) Young-A Heo DRUGS
- Givosiran: First Approval
- (2020) Lesley J. Scott DRUGS
- FDA Approval and Regulation of Pharmaceuticals, 1983-2018
- (2020) Jonathan J. Darrow et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The clinical trial landscape in amyotrophic lateral sclerosis—Past, present, and future
- (2020) Heike J. Wobst et al. MEDICINAL RESEARCH REVIEWS
- Prey for the Proteasome: Targeted Protein Degradation – A Medicinal Chemist´s Perspective
- (2020) Laura M. Luh et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Gene editing and CRISPR in the clinic: current and future perspectives
- (2020) Matthew P. Hirakawa et al. BIOSCIENCE REPORTS
- Antibiotics in the clinical pipeline in October 2019
- (2020) Mark S. Butler et al. JOURNAL OF ANTIBIOTICS
- Facts, Patterns and Principles in Drug Discovery: appraising the Rule of 5 with measured physicochemical data.
- (2020) Christopher P. Tinworth et al. JOURNAL OF MEDICINAL CHEMISTRY
- Critical analysis of antibacterial agents in clinical development
- (2020) Ursula Theuretzbacher et al. NATURE REVIEWS MICROBIOLOGY
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
- (2020) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antisense oligonucleotides for neurodegeneration
- (2020) Blair R. Leavitt et al. SCIENCE
- Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
- (2020) Youhai Jiang et al. Frontiers in Immunology
- Evolving role for pharmacotherapy in NAFLD/NASH
- (2020) Suzanna L. Attia et al. CTS-Clinical and Translational Science
- Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial
- (2020) Panagiotis A Konstantinopoulos et al. LANCET ONCOLOGY
- Targeted degraders clear first safety hurdles
- (2020) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
- (2020) Timothy Miller et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- COVID-19 Therapeutic Options Under Investigation
- (2020) Malak Kaddoura et al. Frontiers in Pharmacology
- Top product forecasts for 2019
- (2019) Lisa Urquhart NATURE REVIEWS DRUG DISCOVERY
- The market for migraine drugs
- (2019) Angela M. Sparrow et al. NATURE REVIEWS DRUG DISCOVERY
- Discovery of the Pan-genotypic Hepatitis C Virus NS3/4A Protease Inhibitor Voxilaprevir (GS-9857): A Component of Vosevi ®
- (2019) James G. Taylor et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- A phase 1, randomized, single ascending-dose study to investigate the safety, tolerability, and pharmacokinetics of DSTA4637S, an anti-Staphylococcus aureus THIOMAB™ antibody-antibiotic conjugate, in healthy volunteers
- (2019) Melicent Peck et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Lofexidine: A Newly FDA-Approved, Nonopioid Treatment for Opioid Withdrawal
- (2019) Bennett Doughty et al. ANNALS OF PHARMACOTHERAPY
- Strategies to address challenges in neuroscience drug discovery and development
- (2019) Patricio O’Donnell et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand
- (2019) Lin Mei et al. Journal of Hematology & Oncology
- A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
- (2019) Frans V. Suurs et al. PHARMACOLOGY & THERAPEUTICS
- Why Some Targets Benefit from beyond Rule of Five Drugs
- (2019) Megan Egbert et al. JOURNAL OF MEDICINAL CHEMISTRY
- ATM in DNA repair in cancer
- (2019) Mei Hua Jin et al. PHARMACOLOGY & THERAPEUTICS
- Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review
- (2019) Guy El Helou et al. Infection and Drug Resistance
- An evaluation of benznidazole as a Chagas disease therapeutic
- (2019) Ivo S. Caldas et al. EXPERT OPINION ON PHARMACOTHERAPY
- Pretomanid: First Approval
- (2019) Susan J. Keam DRUGS
- Lasmiditan: First Approval
- (2019) Yvette N. Lamb DRUGS
- Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease
- (2019) Jinkuk Kim et al. NEW ENGLAND JOURNAL OF MEDICINE
- AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity
- (2019) Jacqueline H. L. Fok et al. Nature Communications
- Therapeutic Antisense Targeting of Huntingtin
- (2019) Anne V. Smith et al. DNA AND CELL BIOLOGY
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- (2019) Zobair M Younossi et al. LANCET
- A resurrection of aducanumab for Alzheimer's disease
- (2019) Lon Schneider LANCET NEUROLOGY
- Antibodies to watch in 2020
- (2019) Hélène Kaplon et al. mAbs
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Doubts persist for claimed Alzheimer's drug
- (2019) Kelly Servick SCIENCE
- PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy
- (2018) Tricia R. Cottrell et al. CANCER JOURNAL
- RNA-Targeted Therapeutics
- (2018) Stanley T. Crooke et al. Cell Metabolism
- Ibalizumab: First Global Approval
- (2018) Anthony Markham DRUGS
- Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections
- (2018) Matt Shirley DRUGS
- Erenumab: First Global Approval
- (2018) Anthony Markham DRUGS
- Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations
- (2018) Robert J. Young et al. JOURNAL OF MEDICINAL CHEMISTRY
- Where Do Recent Small Molecule Clinical Development Candidates Come From?
- (2018) Dean G. Brown et al. JOURNAL OF MEDICINAL CHEMISTRY
- Moxidectin for deworming: from trials to implementation
- (2018) Mathieu Maheu-Giroux et al. LANCET INFECTIOUS DISEASES
- Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis
- (2018) Evelina Tacconelli et al. LANCET INFECTIOUS DISEASES
- Impact of a five-dimensional framework on R&D productivity at AstraZeneca
- (2018) Paul Morgan et al. NATURE REVIEWS DRUG DISCOVERY
- Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
- (2018) Merrill D. Benson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Burosumab Therapy in Children with X-Linked Hypophosphatemia
- (2018) Thomas O. Carpenter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibody–Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review
- (2018) Cédric Rossi et al. Targeted Oncology
- Tafenoquine: First Global Approval
- (2018) James E. Frampton DRUGS
- Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections
- (2018) Sohita Dhillon DRUGS
- Patisiran: First Global Approval
- (2018) Sheridan M. Hoy DRUGS
- Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs
- (2018) Michael D. Shultz JOURNAL OF MEDICINAL CHEMISTRY
- Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
- (2018) Ming Yi et al. Molecular Cancer
- Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1
- (2018) Brinda Emu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study
- (2018) Jong Wook Lee et al. BLOOD
- Fremanezumab: First Global Approval
- (2018) Sheridan M. Hoy DRUGS
- Galcanezumab: First Global Approval
- (2018) Yvette N. Lamb DRUGS
- Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults
- (2018) Yuji Ogawa et al. EXPERT OPINION ON PHARMACOTHERAPY
- Rick Brown
- (2018) NATURE REVIEWS DRUG DISCOVERY
- Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea
- (2018) Stephanie N. Taylor et al. NEW ENGLAND JOURNAL OF MEDICINE
- LAG3 (CD223) as a cancer immunotherapy target
- (2017) Lawrence P. Andrews et al. IMMUNOLOGICAL REVIEWS
- The FDA’s Expedited Programs and Clinical Development Times for Novel Therapeutics, 2012-2016
- (2017) Thomas J. Hwang et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Beyond the Rule of 5: Lessons Learned from AbbVie’s Drugs and Compound Collection
- (2017) David A. DeGoey et al. JOURNAL OF MEDICINAL CHEMISTRY
- Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial
- (2017) Koji Abe et al. LANCET NEUROLOGY
- FDA-Approved Oligonucleotide Therapies in 2017
- (2017) Cy A. Stein et al. MOLECULAR THERAPY
- Clinical trial cycle times continue to increase despite industry efforts
- (2017) Linda Martin et al. NATURE REVIEWS DRUG DISCOVERY
- Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
- (2017) Richard S. Finkel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs
- (2017) Xiulong Shen et al. NUCLEIC ACIDS RESEARCH
- Opportunistic Infections in Biological Therapy, Risk and Prevention
- (2017) Paul A. Bryant et al. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
- Osimertinib: First Global Approval
- (2016) Sarah L. Greig DRUGS
- Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors
- (2016) Ann-Gerd Thorsell et al. JOURNAL OF MEDICINAL CHEMISTRY
- Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial
- (2016) Aung Pyae Phyo et al. LANCET INFECTIOUS DISEASES
- The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
- (2016) Jeff Sevigny et al. NATURE
- Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
- (2016) Axel Hoos NATURE REVIEWS DRUG DISCOVERY
- Aptamers as targeted therapeutics: current potential and challenges
- (2016) Jiehua Zhou et al. NATURE REVIEWS DRUG DISCOVERY
- Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy
- (2016) Robert C. Griggs et al. NEUROLOGY
- Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
- (2016) Dominique P. Germain et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Approval of Flibanserin — Treating Hypoactive Sexual Desire Disorder
- (2016) Hylton V. Joffe et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria
- (2016) Nicholas J. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
- (2016) Y. Pommier et al. Science Translational Medicine
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
- (2016) Jessica S. Brown et al. Cancer Discovery
- Ledipasvir/Sofosbuvir: A Review of Its Use in Chronic Hepatitis C
- (2015) Gillian M. Keating DRUGS
- How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets
- (2015) Bradley C. Doak et al. JOURNAL OF MEDICINAL CHEMISTRY
- ESKAPEing the labyrinth of antibacterial discovery
- (2015) Ruben Tommasi et al. NATURE REVIEWS DRUG DISCOVERY
- Spinal Muscular Atrophy
- (2015) Stephen J. Kolb et al. NEUROLOGIC CLINICS
- Molecular Property Design: Does Everyone Get It?
- (2015) Paul D. Leeson et al. ACS Medicinal Chemistry Letters
- Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study
- (2015) Aaron S Kesselheim et al. BMJ-British Medical Journal
- Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study
- (2015) Aaron S Kesselheim et al. BMJ-British Medical Journal
- The evolution of the regulatory framework for antibacterial agents
- (2014) John H. Rex et al. Annals of the New York Academy of Sciences
- Pembrolizumab: First Global Approval
- (2014) Raewyn M. Poole DRUGS
- Sofosbuvir: First Global Approval
- (2014) Gillian M. Keating et al. DRUGS
- Neurodegenerative disease: Brain windfall
- (2014) Katharine Gammon NATURE
- Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
- (2014) David Cook et al. NATURE REVIEWS DRUG DISCOVERY
- Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
- (2014) Mark S. Sulkowski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Drug Development and FDA Approval, 1938–2013
- (2014) Jonathan J. Darrow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biosimilarity and Interchangeability in the Biologics Price Competition and Innovation Act of 2009 and FDA's 2012 Draft Guidance for Industry
- (2013) By Hannah Koyfman BIOTECHNOLOGY LAW REPORT
- The current development of CNS drug research
- (2013) Gregers Wegener et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Development Times, Clinical Testing, Postmarket Follow-up, and Safety Risks for the New Drugs Approved by the US Food and Drug Administration
- (2013) Thomas J. Moore et al. JAMA Internal Medicine
- CD19 as an attractive target for antibody-based therapy
- (2012) Ohad Hammer mAbs
- Diagnosing the decline in pharmaceutical R&D efficiency
- (2012) Jack W. Scannell et al. NATURE REVIEWS DRUG DISCOVERY
- Recombinant human hyaluronidase PH20 (rHuPH20) facilitates subcutaneous infusions of large volumes of immunoglobulin in a swine model
- (2012) David W. Kang et al. Drug Delivery and Translational Research
- The Novel Anticytomegalovirus Compound AIC246 (Letermovir) Inhibits Human Cytomegalovirus Replication through a Specific Antiviral Mechanism That Involves the Viral Terminase
- (2011) T. Goldner et al. JOURNAL OF VIROLOGY
- The productivity crisis in pharmaceutical R&D
- (2011) Fabio Pammolli et al. NATURE REVIEWS DRUG DISCOVERY
- Aptamers as therapeutics
- (2010) Anthony D. Keefe et al. NATURE REVIEWS DRUG DISCOVERY
- How to improve R&D productivity: the pharmaceutical industry's grand challenge
- (2010) Steven M. Paul et al. NATURE REVIEWS DRUG DISCOVERY
- Fabry disease
- (2010) Dominique P Germain Orphanet Journal of Rare Diseases
- Infectious Complications Associated with Monoclonal Antibodies and Related Small Molecules
- (2009) E. M. T. Salvana et al. CLINICAL MICROBIOLOGY REVIEWS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now